Nicolet Advisory Services LLC Has $355,000 Stock Position in Stryker Co. (NYSE:SYK)

Nicolet Advisory Services LLC increased its stake in Stryker Co. (NYSE:SYK) by 4.4% during the first quarter, Holdings Channel.com reports. The fund owned 1,013 shares of the medical technology company’s stock after buying an additional 43 shares during the period. Nicolet Advisory Services LLC’s holdings in Stryker were worth $355,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Burkett Financial Services LLC acquired a new position in shares of Stryker in the fourth quarter worth approximately $25,000. Farmers & Merchants Trust Co of Chambersburg PA lifted its stake in Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after buying an additional 61 shares during the period. Rogco LP acquired a new position in Stryker in the fourth quarter valued at approximately $30,000. DSM Capital Partners LLC acquired a new position in Stryker in the fourth quarter valued at approximately $34,000. Finally, HBC Financial Services PLLC acquired a new position in Stryker in the fourth quarter valued at approximately $37,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

NYSE:SYK traded up $9.72 during trading on Friday, reaching $340.95. The company’s stock had a trading volume of 2,421,857 shares, compared to its average volume of 967,140. The firm has a market cap of $129.88 billion, a price-to-earnings ratio of 38.92, a price-to-earnings-growth ratio of 2.68 and a beta of 0.89. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71. The firm has a 50 day moving average of $338.30 and a 200-day moving average of $337.75. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $361.41.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.36 by $0.14. The firm had revenue of $5.24 billion during the quarter, compared to the consensus estimate of $5.10 billion. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.14 EPS. Research analysts expect that Stryker Co. will post 11.95 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be paid a dividend of $0.80 per share. The ex-dividend date is Friday, June 28th. This represents a $3.20 annualized dividend and a dividend yield of 0.94%. Stryker’s payout ratio is 36.53%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SYK. The Goldman Sachs Group began coverage on Stryker in a research note on Thursday, May 30th. They issued a “neutral” rating and a $372.00 price target on the stock. Barclays boosted their price target on Stryker from $372.00 to $376.00 and gave the company an “overweight” rating in a research note on Thursday, May 2nd. Stifel Nicolaus upped their target price on Stryker from $350.00 to $375.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Wells Fargo & Company upped their target price on Stryker from $364.00 to $381.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Finally, Roth Mkm upped their target price on Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $372.05.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.